GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genvec Inc (NAS:GNVC) » Definitions » Shiller PE Ratio

Genvec (Genvec) Shiller PE Ratio : (As of May. 05, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Genvec Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Genvec Shiller PE Ratio Historical Data

The historical data trend for Genvec's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genvec Shiller PE Ratio Chart

Genvec Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Genvec Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Genvec's Shiller PE Ratio

For the Biotechnology subindustry, Genvec's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genvec's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genvec's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Genvec's Shiller PE Ratio falls into.



Genvec Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Genvec's E10 for the quarter that ended in Mar. 2017 is calculated as:

For example, Genvec's adjusted earnings per share data for the three months ended in Mar. 2017 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2017 (Change)*Current CPI (Mar. 2017)
=-1.88/102.8622*102.8622
=-1.880

Current CPI (Mar. 2017) = 102.8622.

Genvec Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200706 -6.000 87.906 -7.021
200709 -5.000 87.964 -5.847
200712 -6.000 88.616 -6.965
200803 -8.000 90.090 -9.134
200806 -8.000 92.320 -8.913
200809 -8.000 92.307 -8.915
200812 -7.000 88.697 -8.118
200903 -6.000 89.744 -6.877
200906 -5.000 91.003 -5.652
200909 -4.000 91.120 -4.515
200912 -4.000 91.111 -4.516
201003 -3.900 91.821 -4.369
201006 -3.300 91.962 -3.691
201009 -1.800 92.162 -2.009
201012 -0.700 92.474 -0.779
201103 -1.700 94.283 -1.855
201106 -1.000 95.235 -1.080
201109 -1.100 95.727 -1.182
201112 -2.000 95.213 -2.161
201203 -2.500 96.783 -2.657
201206 -2.800 96.819 -2.975
201209 -3.100 97.633 -3.266
201212 -2.500 96.871 -2.655
201303 -2.400 98.209 -2.514
201306 -2.400 98.518 -2.506
201309 -2.300 98.790 -2.395
201312 -0.600 98.326 -0.628
201403 -0.700 99.695 -0.722
201406 -1.000 100.560 -1.023
201409 -1.000 100.428 -1.024
201412 1.100 99.070 1.142
201503 -0.900 99.621 -0.929
201506 -1.100 100.684 -1.124
201509 -0.900 100.392 -0.922
201512 -0.900 99.792 -0.928
201603 -1.080 100.470 -1.106
201606 -0.600 101.688 -0.607
201609 -0.500 101.861 -0.505
201612 -0.680 101.863 -0.687
201703 -1.880 102.862 -1.880

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genvec  (NAS:GNVC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Genvec Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Genvec's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genvec (Genvec) Business Description

Traded in Other Exchanges
N/A
Address
Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV.
Executives
Wayne T Hockmeyer director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Michael Richman director 2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
Marc R Schneebaum director GENVEC, INC., 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Stefan Loren director 3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Douglas J Swirsky director, officer: President and CEO C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Willam N Kelley director MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Mmcap International Inc. Spc 10 percent owner C/O MOURANT GOVERNANCE SVCS (CAYMAN) LTD, 94 SOLARIS AVE., CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Ecor1 Capital Fund Qualified, L.p. other: See Explanation of Responses 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p. other: See Explanation of Responses 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Zola P Horovitz director C/O GENAERA CORP, 5110 CAMPUS DDRIVE, PLYMOUTH MEETING PA 19462
Cynthia Collins director, officer: President & CEO 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Adel Mahmoud director
Joshua Ruch director 4 DUNE ROAD, EAST QUOGUE NY 11942

Genvec (Genvec) Headlines

From GuruFocus

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 08-07-2009

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 05-08-2009

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-06-2009

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-07-2010

GenVec Inc. Reports Operating Results (10-K)

By gurufocus 10qk 03-11-2011